Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - Seagen Inc. | d481013dex322.htm |
EX-32.1 - EX-32.1 - Seagen Inc. | d481013dex321.htm |
EX-31.2 - EX-31.2 - Seagen Inc. | d481013dex312.htm |
EX-31.1 - EX-31.1 - Seagen Inc. | d481013dex311.htm |
EX-23.1 - EX-23.1 - Seagen Inc. | d481013dex231.htm |
EX-21.1 - EX-21.1 - Seagen Inc. | d481013dex211.htm |
EX-10.56 - EX-10.56 - Seagen Inc. | d481013dex1056.htm |
EX-10.35 - EX-10.35 - Seagen Inc. | d481013dex1035.htm |
EX-10.29 - EX-10.29 - Seagen Inc. | d481013dex1029.htm |
EX-10.18 - EX-10.18 - Seagen Inc. | d481013dex1018.htm |
10-K - FORM 10-K - Seagen Inc. | d481013d10k.htm |
Exhibit 10.17
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Inspiring Science
Amendment to SGD-1006
Commercial Supply Agreement executed on 1 December 2010.
[*] Manufacturing Controls Price Increase
27 August 2013
Vaughn Himes
VP, Manufacturing
21823- 30th Drive S.E.
Bothell, WA 98021
Dear Vaughn:
Based on the recent Safebridge assessment of SGD-1006 and SGD-1010 occupation exposure level (OEL), a [*]classification has been applied to these molecules. This change in classification will require additional manufacturing containment and precautions for these [*].
This letter serves to amend the SGD-1006 pricing outlined in the supply agreement executed on 1 December 2010. The purpose of this costing revision is to capture the additional time and materials required to manufacture SGD-1006 [*].
[*] implementation will require extended suite time, additional materials, and FTEs. It is estimated that the implementation will result in a cost increase of [*]. Based on this assessment Seattle Genetics have agreed to increase payment for the [*]. The revised price per gram is outlined in the table below:
Revised SGD-1006 Pricing Schedule:
SG6 Quantity (g) | Current Price ($)/g | Batch Cost Increase | Revised Cost/g | |||
[*] | [*] | [*] | [*] |
[*]
Inspiring Science
IN WITNESS WHEREOF, the parties have executed this Amendment, effective as of the Amendment Effective Date.
Agreed and Accepted:
SAFC, Inc. | Seattle Genetics, Inc. | |||||||
By: | /s/ Gills Cotter |
By: | /s/ Clay B. Siegall | |||||
Name: | Gills Cotter |
Name: | Clay B. Siegall | |||||
Title: | President |
Title: | President and CEO | |||||
Date: | December 15, 2014 |
Date: | January 20, 2014 |